JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management
January 26, 2023
In meetings hosted by Nasdaq MarketSite, the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS, January 26, 2023 – JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk... READ MORE
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
January 10, 2023
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a... READ MORE
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC
September 22, 2022
The acquisition of Soin will provide JanOne with its second clinical stage product LAS VEGAS, Sept. 16, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire Soin Therapeutics LLC and its product,... READ MORE
JanOne Inc. Announces an Improved Formulation of JAN101
June 28, 2022
Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 LAS VEGAS, June 28, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of... READ MORE
June 7, 2022
Issuance of U.S. Patent 11,247,902 B2 Further Bolsters JanOne Inc.'s Intellectual Patent Portfolio LAS VEGAS, June 7, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was issued that covers a method of improving nerve function using JAN101. JAN101... READ MORE
JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction
June 1, 2022
Sale of GeoTraq allows JanOne to focus on core business strategy LAS VEGAS, May 31, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), announced today that it has sold substantially all of the assets, and none of the liabilities, of GeoTraq Inc. ("GeoTraq"), its wholly-owned subsidiary, to SPYR Technologies Inc. ("SPYR"). "We believe this transaction further... READ MORE
JanOne Inc. Develops Plan for Treating Methamphetamine Use Disorder
January 4, 2022
JanOne Inc. has Started Working on Developing New Treatments for Treating the ~1.5 Million Americans who Abuse Methamphetamines LAS VEGAS, Jan. 4, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - previously... READ MORE
October 27, 2021
Minneapolis – October 27, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), launched two new appliance recycling programs in Northern California, with a focus on decreasing the release of greenhouse gas (GHG) and ozone-depleting emissions into the atmosphere. The primary goal of these programs is to prevent the release... READ MORE
October 19, 2021
MINNEAPOLIS, Oct. 19, 2021 /PRNewswire/ -- ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), has seen major growth in its appliance replacement programs throughout the past 12 months, with the addition of new contracts signed this year that total more than $3 million. It is estimated that these new contracts could... READ MORE